Iguana Healthcare Management LLC purchased a new position in Ascendis Pharma A/S (NASDAQ:ASND) during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 30,000 shares of the biotechnology company’s stock, valued at approximately $1,088,000. Iguana Healthcare Management LLC owned about 0.08% of Ascendis Pharma A/S at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Bank of Montreal Can lifted its holdings in shares of Ascendis Pharma A/S by 127.4% in the 2nd quarter. Bank of Montreal Can now owns 4,535 shares of the biotechnology company’s stock worth $126,000 after purchasing an additional 2,541 shares during the last quarter. Bank of America Corp DE raised its stake in Ascendis Pharma A/S by 23.6% during the 1st quarter. Bank of America Corp DE now owns 5,345 shares of the biotechnology company’s stock valued at $150,000 after acquiring an additional 1,020 shares in the last quarter. Victory Capital Management Inc. bought a new stake in Ascendis Pharma A/S during the 3rd quarter valued at $194,000. Aperio Group LLC bought a new stake in Ascendis Pharma A/S during the 3rd quarter valued at $241,000. Finally, Deschutes Portfolio Strategy LLC bought a new stake in Ascendis Pharma A/S during the 2nd quarter valued at $238,000. 78.93% of the stock is currently owned by institutional investors and hedge funds.

Shares of Ascendis Pharma A/S (NASDAQ ASND) opened at $37.39 on Thursday. Ascendis Pharma A/S has a 12 month low of $19.21 and a 12 month high of $42.00.

Several analysts have weighed in on ASND shares. Bank of America lifted their target price on Ascendis Pharma A/S from $36.00 to $46.00 in a research note on Thursday, September 28th. Wells Fargo & Company reaffirmed a “buy” rating and set a $51.00 target price on shares of Ascendis Pharma A/S in a research note on Friday, September 22nd. HC Wainwright reaffirmed a “buy” rating on shares of Ascendis Pharma A/S in a research note on Wednesday. Leerink Swann reaffirmed a “hold” rating and set a $28.00 target price on shares of Ascendis Pharma A/S in a research note on Friday, September 1st. Finally, Credit Suisse Group reaffirmed an “outperform” rating and set a $50.00 target price (up previously from $30.00) on shares of Ascendis Pharma A/S in a research note on Friday, September 22nd. Two research analysts have rated the stock with a sell rating, two have given a hold rating and six have issued a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus target price of $36.45.

TRADEMARK VIOLATION NOTICE: “Iguana Healthcare Management LLC Purchases New Holdings in Ascendis Pharma A/S (ASND)” was originally posted by Daily Political and is the sole property of of Daily Political. If you are reading this piece on another publication, it was illegally copied and republished in violation of US and international copyright & trademark law. The original version of this piece can be accessed at https://www.dailypolitical.com/2017/12/14/iguana-healthcare-management-llc-purchases-new-holdings-in-ascendis-pharma-as-asnd.html.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in applying its TransCon technology to develop sustained release prodrug therapies with several product candidates in clinical and preclinical development. The Company is developing its product candidate, TransCon human growth hormone (TransCon hGH) for once-weekly administration to treat growth hormone deficiency (GHD) and other indications.

Institutional Ownership by Quarter for Ascendis Pharma A/S (NASDAQ:ASND)

Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.